DocTalk Tweet Chat "The Potential of TAVR" Scheduled for August 28


A primary investigator-led discussion will tap into how invasive procedures have become more embraced in US cardiology.

Earlier this month, the US Food and Drug Administration (FDA) approved the expanded use of Edwards SAPIEN 3 transcatheter aortic valve replacement (TAVR) to include the treatment of severe, symptomatic aortic stenosis in patients at low risk of open-heart surgery.

The indication made the innovative cardiovascular procedure possible for high-risk and low-risk surgery patients—and brought further discussion to what the future of invasive versus non-invasive care looks like in US patients.

This week’s #DocTalk is untapping the potential of TAVR, with the help of a leading expert on the procedure.

#DocTalk is a weekly conversation featured on Twitter that focuses on the biggest issues in healthcare today. Join us on Wednesday, August 28 at 12 PM EST for the start of our chat, featuring Michael Mack, MD, FACC, Chair of the Cardiovascular Governance Council, Medical Director of Cardiovascular Surgery at Baylor Scott & White (BSW) The Heart Hospital — Plano, and Medical Director of the Cardiovascular Service Line, at BSW.

Mack, the co-primary investigator of the Placement of Aortic Transcatheter Valves (PARTNER) 3 Trial, will be leading discussion from the BSW twitter account (@bswhealth) on the following questions:

  • The FDA’s approval of TAVR is welcome news for many. How does it affect involved care providers and their patients? Who is the right TAVR candidate?
  • What are some of the variables that should considered and discussed with patients before going with TAVR?
  • How should TAVR be implemented and managed in interested programs?
  • Do you see the shift to minimally-invasive options like TAVR impacting surgical training and education?
  • What’s next for TAVR research?
  • What has helped drive the increase of device-focused clinical research in the US?

We invite all interested Twitter users to participate in the chat and contribute their own perspective and questions.

Be sure to search for “#DocTalk,” follow MD Mag on Twitter (@MDMagazine), and look for the social media icon signifying the chat:

#DocTalk, tweet chat, TAVR

If you’re a frequent Twitter user with a background in healthcare and interest in leading a #DocTalk chat with your colleagues, contact us here.

Related Videos
Video 2 - "Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment "
Video 1 - "Novel Cardio Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause "
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Heart Failure Treatment Outcomes and Contraindications
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
© 2024 MJH Life Sciences

All rights reserved.